Car Nk

BiCAR-NK cells (ROBO1 CAR-NK cells)

BiCAR-NK cells (ROBO1 CAR-NK cells) is flagged as a low confidence because it has an active early-phase oncology cell-therapy trial at Asclepius Technology Company Group (Suzhou) Co., Ltd., with a unlinked patent signal linked through public patent-search heuristics. Manual review is still required.

Asset overview

Program snapshot

Target: Unknown

Cell type: NK_CELL

Indications: Pancreatic Cancer

Sponsor: Asclepius Technology Company Group (Suzhou) Co., Ltd.

Institution: Asclepius Technology Company Group (Suzhou) Co., Ltd.

Clinical evidence

Trial footprint

Phase: Phase1

Status: Unknown

Trial count: 1

Active trials: 0

First posted: May 8, 2019

Last updated: May 8, 2019

Signal summary

IP and BD posture

IP signal: Unlinked

BD label: Low Confidence

Confidence: Low

Manual review required: Yes

Scores

Deterministic scoring

Clinical translation0
IP linkage0
Licensing clarity2
Strategic interest2
Source

Public trial record

Review the underlying ClinicalTrials.gov record and treat Treelip output as a prioritization layer, not a final diligence conclusion.

Open source study

NCT IDs: NCT03941457